FATE Q4 2017 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$142M

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M+0.0% YoY

Gross Profit

-$9M-862.7% margin

Operating Income

-$12M-1192.2% margin

Net Income

-$12M-1216.8% margin

EPS (Diluted)

$-0.29

QoQ Revenue Growth

+0.1%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$12M

Stock-Based Comp.

$895,000

Balance Sheet

Total Assets

$105M

Total Liabilities

$28M

Stockholders' Equity

$77M

Cash & Equivalents

$89M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$1M	+0.0%
Gross Profit	-$9M	-$5M	-70.3%
Operating Income	-$12M	-$8M	-60.0%
Net Income	-$12M	-$8M	-57.4%